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Abstract
Expression of class III -tubulin ( III-tubulin) correlates with tumor progression and resistance to taxane-based therapies for severalβ β
human malignancies but its use as a biomarker of tumor behaviour in prostate cancer (PCa) remains largely unexplored. Here, we
describe III-tubulin immunohistochemical staining patterns of prostate tumors obtained from a broad spectrum of PCa patients,β
some of whom subsequently received docetaxel therapy for castration-resistant prostate cancer (CRPC). Elevated III-tubulinβ
expression was significantly associated with tumor aggressiveness in PCa patients with presumed localized disease as it was found to
be an independent marker of biochemical recurrence after treatment. Additionally, III-tubulin expression in tumor cells was anβ
independent predictor of lower overall survival for patients receiving docetaxel-based chemotherapy for CRPC. Manipulation of β
III-tubulin expression in human prostate cancer cell lines using a human III-tubulin expression vector or III-tubulin siRNA alteredβ β
cell survival in response to docetaxel treatment in a manner that supports a role for III-tubulin expression as a mediator of PCa cellβ
resistance to docetaxel therapy. Our findings suggest a role for III-tubulin as candidate theranostic biomarker to predict theβ
response to docetaxel-based chemotherapy as well as to target for treatment of docetaxel-resistant CRPC.
MESH Keywords Aged ; Antineoplastic Agents ; therapeutic use ; Cell Line, Tumor ; Cell Survival ; drug effects ; genetics ; Drug Resistance, Neoplasm ; genetics ; 
Humans ; Immunoblotting ; Immunohistochemistry ; Male ; Middle Aged ; Multivariate Analysis ; Neoplasm Invasiveness ; Orchiectomy ; Prognosis ; Prostate ; drug effects ; 
metabolism ; surgery ; Prostatectomy ; Prostatic Neoplasms ; drug therapy ; metabolism ; pathology ; RNA Interference ; Survival Analysis ; Taxoids ; therapeutic use ; Tubulin ;
biosynthesis ; genetics ; Tumor Markers, Biological ; biosynthesis ; genetics
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INTRODUCTION
Prostate cancer (PCa) is the most common solid malignancy and the second leading cause of death attributable to cancer in men ( ).1 
Despite the widespread use of PSA testing to screen for early stage PCa, men continue to be diagnosed with locally advanced or metastatic
disease, and approximately 30  of newly diagnosed patients treated with curative intent will eventually relapse during follow-up ( ).% 2 
Treatments at this advanced stage usually include androgen deprivation therapy to deplete systemic androgens in patients, thus reducing
the levels of a known PCa growth factor. This treatment is most often only transiently effective because prostate tumor cells can progress
to a seeming androgen-independent growth phase now diagnosed as castration resistant prostate cancer (CRPC) ( ). Once at this stage,3 
docetaxel-based chemotherapy has been shown to improve though the survival advantage is relatively limited ( , ). At this time, several4 5 
molecular markers have been proposed to have dependent or independent utility for PCa patient prognostic assessments ( , ) but these6 7 
latter biomarkers remain unproven. Here, we discuss our efforts to evaluate the potential utility of class III -tubulin for purposes ofβ
prognostication of PCa patient response to early, localized therapy or to late-stage, taxane-based chemotherapy.
Taxanes constitute an important group of chemotherapeutic agents that specifically target the -tubulin subunit of microtubules. Byβ
targeting microtubule activity, taxanes can block cell mitosis and induce apoptosis, especially in tumor cells ( ). A growing body of8 
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preclinical and clinical data now suggests that increased expression of one particular -tubulin isoform, class III -tubulin ( III-tubulin),β β β
confers cancer cell resistance to taxanes ( ) and that III-tubulin resistance to taxanes is clinically relevant for human lung, breast,9 –11 β
and ovarian cancers ( ). For these human malignancies, high tumor cell expression of III-tubulin was associated with significantly12 β
poorer survival rates in patients treated with taxane-based chemotherapy ( ). For lung cancer, one study suggested that tumor cell 13 –17 β
III-tubulin expression was a prognostic factor for men who did not receive adjuvant chemotherapy ( )18 
For PCa, despite evidence from in vitro studies showing that -tubulin isotype expression was altered in paclitaxel-resistant cells, thereβ
has been only little informative clinical data evaluating the prognostic or predictive value of III-tubulin expression in patient tumor cells (β
, ). Previously, we showed that expression of III-tubulin was increased in castration-resistant prostate cancers and that expression of19 20 β
this tubulin isoform might have a role in progression to CRPC ( ). The aim of the present study was to determine whether III-tubulin21 β
expression might have prognostic value for hormone-na ve PCa patients treated by surgery or for CRPC patients treated with taxane-basedï
therapy (docetaxel). Here we evaluated clinical prostate cancer specimens for expression levels of III-tubulin by immunohistochemistryβ
and we manipulated III-tubulin expression in prostate cancer cell lines to determine the effects of this manipulation on in vitroβ
responsiveness to docetaxel.
MATERIALS AND METHODS
Cell culture
Human prostate cancer cell lines LNCaP (clone FGC), 22Rv1, and DU145 were obtained from American Type Culture Collection
(Manassas, VA, USA). Cells were maintained in RPMI 1640 supplemented with 10  FBS and penicillin/streptomycin. For this study low%
passage cells were used (<20 passages). The LNCaP-AI variant (passage 16 to 20) was derived from LNCaP cultures maintained more
than 18 months growth in androgen depleted medium (phenol red-free RPMI supplemented with 10  charcoal-stripped FBS). LNCaP and%
22Rv1 were authenticated through cell morphology monitoring, response to androgen treatment, and expression of Androgen Receptor
which harbor mutations in these lines ( ). DU145 was authenticated by lack of AR expression, expression of mutant TP53 ( ), and22 –24 24 
assessment of the invasive behavior using Boyden chamber assays.
Western blot analysis
Protein lysates were prepared in the RIPA buffer (radioimmunoprecipitation assay lysis buffer) supplemented with protease inhibitor
cocktail (Roche Diagnostics, Basel, Switzerland) and phosphatase inhibitors (25mmol/L orthovanadate and 50 mmol/L NaF)
(Sigma-Aldrich). The total protein concentration of the soluble extract was determined using the Bicinchoninic Acid Kit (Sigma-Aldrich).
Each protein sample (30 g) was resolved to SDS PAGE, transferred onto a polyvinylidene difluoride membrane (Millipore, Molsheim,μ –
France) and incubated with a monoclonal antibody against III-tubulin (1 : 10 000; clone TUJ1; Covance, Emeryville, CA) or -actin (1 :β β
16 000; AC-15; Sigma-Aldrich). Primary antibodies against the other -tubulin isotypes were from Abcam (San Francisco, CA). Immuneβ
complexes were visualised by enhanced chemiluminescence detection (ECL plus kit, GE Healthcare, Little Chalfont, UK).
cDNA synthesis and real-time PCR
Quantitative PCR was carried out using SYBR Green dye on an Applied Biosystems 7000 Real Time PCR system (Applied
Biosystems, Foster City, CA, USA). The conditions for RT PCR have been described previously ( ). The amount of III-tubulin mRNA– 25 β
levels relative to the housekeeping gene Ribosomal Protein, large, P0 (RPLP0) was determined on the basis of the comparative threshold
cycle CT method (2 ). The primer sequences for III-tubulin and RPLP0 have been described previously ( , ). CT −Δ Δ β 25 26 
Construction of bIII-tubulin expression vector and Generation of stable bIII-tubulin overexpressing cells
The ORF encoding bIII-tubulin was purchased from Invitrogen (Ultimate ORF clone, clone ID IOH3755, NM 00608.2). The
bIII-tubulin ORF was provided in the Gateway entry vector pENTR 221. The bIII-tubulin expression was constructed by recombining the
bIII-tubulin pENTR 221 into the destination vector pcDNA 3.2/V5-DEST (Invitrogen) via the LR reaction according to the manufacturer s’
instructions (Gateway LR clonase II enzyme mix, Invitrogen). The resulting vector was designated as pcDNA-TUBB3. LNCaP and
DU145 cells were seeded at the density of 1.5x10 cells in 100-mm culture dishes in RPMI 1640 supplemented with 10  FBS. The next5 %
day, cells were transfected with 4 g of pcDNA-TUBB3 vector using Lipofectamine 2000 reagent (Invitrogen) following the manufacturerμ ’
s instructions. Cells were selected in geneticin (G418, 400 g/mL) for 3 weeks. Resistant colonies were isolated and allowed to grow asμ
monoclonal population. Clones expressing the different levels of bIII-tubulin were selected, as determined by western blot analysis, for
further studies.
siRNA transfection
Small interfering RNA (siRNA) against TUBB3, and control NonTargeting siRNA were obtained from Invitrogen, Inc. Three specific
Stealth RNAi sequences were tested: TUBB3HSS115886 (5 -GACAUCUCUUCAGGCCUGACAAUUU-3 ), TUBB3HSS115887 (5′ ′ ′
-GCAUCAUGAACACCUUCAGCGUCGU-3 ), and TUBB3HSS173592 (5 -CAGCUGGAGCGGAUCAGCGUCUACU-3 ). The non′ ′ ′
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silencing control siRNA, which has no sequence homology to any known human gene sequence, was used as a control for
nonsequence-specific effects in all experiments.
Subconfluent human prostate cells were transfected with siRNA by using Lipofectamine 2000 (Invitrogen) following the manufacturer
s instructions. 72 hours after the transfection, the efficacy of the siRNA knock down was assessed by qRT-PCR and by immunoblotting.’
The optimal amount of siRNA used for transfection was determined as being 50 nmol/L and the best siRNA sequence allowing to reduce
more than 70  of bIII-tubulin expression was identified as the sequence TUBB3HSS115887.%
Docetaxel dose response curve
To assess the effect of III-tubulin overexpression on chemoresistance, 1x10 cells were seeded in 96-well microtiter plates. The nextβ 4 
day, cells were treated with docetaxel at growing concentrations for 72 hours. Cell viability was determined by 3- 4,5-dimethylthiazol-2-yl[ ]
-2,5-diphenyl tetrazolium bromide (MTT) assay.
To assess the effect of the combination treatment of III-tubulin silencing plus docetaxel, 22Rv1 cells were transfected with 50 nM ofβ
stealth siRNA against III-tubulin or control vector as described above and then treated with docetaxel at various concentrations for threeβ
days. Cell viability was then determined by MTT assay.
The cell survival curve was presented as the percentage of surviving cells versus the concentration of docetaxel. The IC values were50 
defined as the concentration of drug required for 50  cell survival, and were calculated using a logarithmic regression. Results were%
expressed as means  SEM. Each assay was done in triplicate and was repeated on three separate experiments.±
Patients and Tissue Samples
Written informed consent was obtained. The study included :
(i) Two hundred and fifty eight patients who had undergone RP for localized PCa between November 1988 and May 2007.
Demographics, clinical and biological data, pathologic parameters, and outcomes in terms of PSA recurrence and adjuvant treatment of
258 patients with hormone-na ve PCa (HNPC) was collected prospectively in a database and reviewed in a retrospective manner. Clinical,ï
biological, and pathologic parameters and follow-up data are listed in . No patient had received neoadjuvant therapy.Table 1 
(7) Thirty seven patients with CRPC stage and analyzable initial hormone-naive tissue who received docetaxel-based chemotherapy as
first-line treatment between January 2002 and July 2008. Demographics, clinical and biological data, pathologic parameters, and outcomes
in terms of PSA were collected prospectively in a database and reviewed in a retrospective manner. The mean age was 68.1 years and the
mean PSA level was 135.0 ng/ml at PCa diagnosis. The median Gleason score was 8 at diagnosis. Bone metastases were present in 21
patients at PCa diagnosis. Docetaxel-based chemotherapy was administered for clinical and/or biochemical progression in patients with
CRPC after a mean duration of androgen-ablation therapy of 33.2 months. The patient s hormone-refractory status was defined as a’
progressive increase in PSA level after androgen blockade. Hormonal castration had to be biologically confirmed. Chemotherapy was
combined with low-dose orally administered prednisone.
Formalin-fixed, paraffin-embedded specimens were obtained from the Department of Pathology at the Henri Mondor Hospital, Cr teil,é
France. Immunostaining was performed: (i) on the initial prostatic biopsies of 37 patients who had received first-line docetaxel-based
chemotherapy; and ( ) on tissue microarrays (TMA) for the HNPC patient s cohort. When considering TMAs, for each PCa case, 47 ’
replicate cores (diameter 0.6 mm) were obtained from cancer foci and four additional cores were also taken from nonneoplastic areas as
previously described 25 .[ ]
Immunohistochemistry (Supplementary Method)
Immunostaining was done on 5- m tissue sections mounted on silane-coated slides. III-tubulin protein expression was evaluatedμ β
using a monoclonal antibody specific for the III-tubulin isotype (1:500; clone TUJ1; Covance, Emeryville, CA).β
A numerical score was assigned for the epithelial cells of each specimen. Samples with no stained tumour cells were scored as 0. A
score of 1, 2, or 3 was assigned to samples with weak, moderate, or strong staining, respectively, independently of the proportion of
stained tumour cells. The proportion of immunostained tumour cells was also assessed. For TMAs analysis, the mean of staining in the 4
neoplastic cores was considered. Only cytoplasmic staining was taken into account. All of the slides were independently evaluated by 3
observers (GP, ST, YA). Observers were blinded to the patients  adjuvant treatment, final pathologic assessment, and outcome. Interrater’
reproducibility was 95 . Different scores were reassessed and consensus between observers was defined. Staining intensity seen in nerves%
and axons served as an internal positive control. The absence of immunostaining in red cells was used as negative control ( ).27 
Photomicrographs were taken using a Zeiss Axioplan2 microscope (Carl Zeiss, Le Pecq, France) from imaging platform (INSERM, U955,
UPEC).
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Statistical analysis
Null expression (0  of stained cells) and weak to strong expression (score 1 to 3, and 5  of stained cells) were grouped separately as% ≥ %
dichotomic variables for statistical analysis.
The Student-t test was used for continuous data. The Mann-Whitney test and the Kruskal-Wallis test were used when data were not
normally distributed. Qualitative data were tested using a Chi-square test or Fisher s test as appropriate. The Gleason score was’
dichotomized according to the definition of high-risk prostate cancer as follows: Gleason score<8 versus 8 ( ). Survival curves were≥ 2 
generated by the Kaplan-Meier method and compared using the log-rank test. The Cox proportional hazards model was used to evaluate
the independent value of III-tubulin expression among commonly used prognostic factors. Hazard ratios (HR) were presented with 95β %
CI.
(i) In the CRPC cohort, the starting point of the analysis was the first cycle of chemotherapy. The PSA Working Group criteria were
used to evaluate PSA responses: we chose a decrease of >75  from the baseline PSA level as the criterion for PSA response ( ). The% 28 
primary endpoint was overall survival (OS) defined as the time from the start of chemotherapy until death from any cause or last follow-up
for censored patients. Time-to-progression was defined as the time between the first cycle of chemotherapy and an elevated PSA finding.
(7) In the HNPC cohort, Biochemical RFS was analyzed. The day of surgery was reported as the starting point of analysis. Recurrence
was defined as the first detectable elevation of PSA above 0.20 ng/ml (at least two consecutive measurements).
A value of p<0.05 was considered statistically significant, and all p values were two-sided. SPSS 13.0 (Chicago, Illinois) software was
used for statistical analyses.
RESULTS
Prognostic value of III-tubulin expression for prostate cancer recurrence in hormone-na ve PCa patients treated by radicalβ ï
prostatectomy
We had previously reported that III-tubulin was expressed significantly lower in hormone na ve PCa (HNPC) as compared toβ ï
castration resistant PCa (CRPC). In our previous study, however, the small patient sample size in the HNPC group (n 74) prevented us=
from deriving any statistically reliable association with other patient prognostic factors ( ). Here, we extended our assessment of 21 β
III-tubulin expression to PCa-containing specimens obtained from 258 PCa patients that were treated by radical prostatectomy ( ).Table 1 
We identified III-tubulin expression in 43 of the 258 specimens from patients with HNPC (16.7 , ). Strong III-tubulinβ % Table 2 β
immunostaining (score of 3.0) was detected in 6.2  of tumors. When III-tubulin expression was observed, the percentage of% β
positively-stained tumor cells showed a wide range of variability (range: 5 100 ; mean 25.8 ; median 10 ). Representative examples of– % % %
immunostaining are shown in . III-tubulin expression was not detected in non-malignant prostate basal or luminal epithelialFig. 1A C – β
cells adjacent to the tumor. Correlations of III-tubulin immunostaining with histoprognostic parameters are described in . Weβ Table 2 
found that positive immunostaining was significantly associated with a Gleason score 8 (p 0.001; OR 3.17), a primary Gleason grade of≥ =
4 or 5 (p 0.013; OR 2.28), a pT stage  3 (p 0.042; OR 1.97), an extraprostatic extension (p 0.028; OR 2.10) and positive lymph nodes (p= ≥ = =
0.034; OR 3.05). It is noteworthy that III-tubulin expression was also significantly associated with a high risk for biochemical= β
recurrence (p 0.029: OR 2.15). The intensity of immunostaining was also correlated with the histoprognostic parameters. A strong=
immunostaining, defined by a staining score of 3 was also markedly associated with a Gleason score 8 (p<0.001), extraprostatic extension≥
(p<0.001), positive surgical margins (p 0.025), pT stage (p<0.001), and positive lymph nodes (p 0.043), when compared with a= =
null-to-moderate staining (score 0, 1, or 2). The 3-year and 5-year recurrence free survival (RFS) was 84.5  and 75.4 , respectively, in% %
patients with no III-tubulin expression in the prostate tumor. By contrast, the 3-year and 5-year RFS was 72.4  and 59.4 , respectively,β % %
in patients expressing III-tubulin in prostate tumor cells. The log-rank test was significant with a p value of 0.002 ( ). In patientsβ Fig. 1D 
with favorable pathological features (Gleason <8, pT2 cancer, and negative surgical margin), the 5-year RFS was 91.7  in % β
III-tubulin-negative patients versus 79.6  in III-tubulin-positive patients (p 0.006). Furthermore, in multivariate analysis using a Cox% β =
model taking into account Gleason score, pT stage, and surgical margin status, III-tubulin expression was an independent predictor ofβ
biochemical recurrence (p 0.029; HR 1.95 1.07 3.55 ).= [ – ]
Increased expression of III-tubulin in prostate cancer cell lines in response to in vitro docetaxel treatmentβ
We previously reported that III-tubulin expression was increased in LNCaP cells, ( ) that were grown in androgen depletedβ 21 
medium or in tumor xenografts from these cells after castration of the host mouse. In the present work, we tested whether docetaxel
treatment could affect III-tubulin expression in two androgen-independent (AI) PCa cell lines; LNCaP-AI that expresses low levels of β β
III-tubulin or 22Rv1 that endogenously expresses higher levels of III-tubulin. LNCaP-AI variant cells were treated with docetaxel at 3β
nmol/L for up to 30 days. As shown in , using Western blots to assess the levels of expressed III-tubulin protein, expressionFigure 2A β
was continuously elevated by exposure to docetaxel over the time course of the experiment. It is noteworthy that the class II -tubulin, anβ
isotype known to be predominantly expressed in the brain also increased along with total -tubulin under docetaxel exposure whereas noβ
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significant increase was seen for I and IV isotypes ( and ). To corroborate these findings, we set out toβ β Fig. 2A Supplementary Fig. S1 
further characterize the expression of -tubulin isotypes in 22Rv1 under exposure to docetaxel at 15 nM for 72 hrs. The 22Rv1 PCa cellβ
line is derived from a primary tumor xenograft, CWR22, that relapsed during androgen ablation ( ). These cells express at least three29 
androgen receptor isoforms that appear to be constitutively active, likely promoting proliferation as well as the expression of multiple
AR-dependent genes in a ligand-independent manner ( ). Consistent with earlier observations, upregulation of III-tubulin protein (23 β Fig.
and ) as well as mRNA levels ( ) was evident in docetaxel-treated 22Rv1 cells.2B Supplementary Fig. S2A Supplementary Fig. S2B 
The II- and total protein levels were similarly increased in docetaxel-treated cells in contrast to that found for I and IV isotypes.β β β
Together, these data demonstrate that both acute and chronic exposure of AI prostate cancer cells to docetaxel upregulates III-tubulinβ
along with a seeming general increase of total -tubulin.β
Stable over-expression of III-tubulin in prostate cancer cell lines confers resistance to docetaxelβ
To assess whether over-expression of III-tubulin was sufficient to confer resistance to docetaxel in prostate cancer cells, weβ
established PCa cell clones, from LNCaP or DU145 cells, stably expressing the human TUBB3 gene ( III-tubulin transfected clones)β
under the control of a CMV promoter. The AR negative DU145 line is derived from a brain metastasis. These cells might represent a very
aggressive stage of prostate cancer as reflected by their growth rate and their invasive behaviour in vitro and in vivo ( ). LNCaP cells are30 
androgen-sensitive prostate cancer cells originated from a lymph node metastasis. Lymph nodes are the most common and earliest sites for
prostate cancer metastasis thus rendering this model particularly attractive for the research community ( ). Differential expression of 22 β
III-tubulin protein between control vector-transfected LNCaP cells and TUBB3-transfected clones was established by Western blot
analysis ( ). Despite some decrease of II isotype was seen in III-tubulin transfected LNCaP cells ( III-tubulin clone 1), forcedFig. 2C β β β
expression of TUBB3 did not seem to affect consistently the expression of the -tubulin isotypes. Interestingly, the III-tubulinβ β
overexpressing LNCaP cells had a neuroendocrine-like appearance ( ) suggesting that forced expression of Supplementary Fig. S3 β
III-tubulin is associated with a trans-differentiation process that has been frequently described for these cells ( , ). To examine the31 32 
effects of III-tubulin over-expression, we measured the half-time inhibitory concentration (IC50) of docetaxel assessed by measuring cellβ
viability at 72 hrs after exposure. The cell viability assays showed that III-tubulin transfected LNCaP cells ( III-tubulin clone 1 and β β β
III-tubulin clone 7) were significantly more resistant to docetaxel treatment than control vector-transfected LNCaP cells with a 6.6-fold
increase in the IC (33.1 versus 5.0 nmol/L, p<0.001, ). A significant difference between clones and control cell survival was50 Fig. 2D 
already achieved at 2 nmol/L docetaxel and persited up to 50 nmol/L docetaxel treatment (p<0.001). III-tubulin transfected LNCaP cellsβ
were again poorly sensitive to docetaxel when higher doses were tested (Supplementary Fig. S4) Having established that III-tubulin hasβ
severe implications for docetaxel resistance in LNCaP cells, we sought to determine if this could be due in part to an effect of III-tubulinβ
on cell proliferation. To this end, cell proliferation was assayed in the absence of drug. Cell doubling times for vector-transfected LNCaP
and III-tubulin transfectants were estimated at 31h and 44h, respectively (supplementary Table 1). Two III-tubulin transfected DU145β β
clones were also selected for subsequent treatment including 1 clone expressing high levels of III-tubulin ( III-tubulin clone 7), and 1β β
clone expressing moderate III-tubulin ( III-tubulin clone 5) at a level similar to that found in parental or control vector-transfected DUβ β
145 cells ( ). The cell viability assays showed that bIII-tubulin-transfected clone 7 was significantly more resistant to docetaxelFig. 3A 
treatment compared to clone 5 or control vector-transfected DU 145 cells with a 2-fold increase in IC (11.1 versus 5.1 nmol/L, p<0.001, 50 
). A significant difference in cell viability between clone 7 and control cells was already achieved at 5 nmol/L (p<0.001). ThereFig. 3B 
were no noticeable morphological differences between the parental vector-transfected DU145 and either of the two sublines. Nor were
there any evident differences in growth rates noted during standard passage and cell proliferation assays of the sublines compared to the
vector-transfected or parental cells (supplementary Table1).
βIII-tubulin silencing increases sensitivity to docetaxel
To further ascertain a role for III-tubulin in chemoresistance to docetaxel, siRNAs directed against III-tubulin was used toβ β
knockdown endogenous III-tubulin expression in 22Rv1 cells. The targeting siRNA with the highest reduction of III-tubulin wasβ β
selected for further study based on RT-PCR and Western-blot analysis for effects on III-tubulin mRNA and protein. III-tubulin mRNAβ β
levels were decreased by 70  using this siRNA and III-tubulin knockdown was confirmed by Western blot analysis after 3 and 6 days (% β
). siRNA mediated loss of III-tubulin did not appear to affect the other III-tubulin isotypes (supplementary Figure S5). AnFig. 3C β β
assessment of the doubling times revealed that concomitantly with the loss of III-tubulin upon III-tubulin siRNA treatment, there was aβ β
trend towards an increase in cell growth (supplementary table 1). Docetaxel was then added to the growth medium of control cells or
targeting siRNA-treated cells 72 hours after the transfection. Seventy hrs later, targeting siRNA-transfected 22Rv1 cells were found to be
more sensitive to docetaxel treatment at all doses tested compared to the control 22Rv1 cells. Overall, III-tubulin siRNA-transfectedβ
22Rv1 cells were found to be 2-fold more sensitive to docetaxel (IC of 4.4 versus 8.5 nmol/L, p<0.001, ) than controls. These50 Fig. 3D 
results indicate that III-tubulin silencing sensitizes AI PCa cells to docetaxel.β
Predictive value of early III-tubulin expression in a docetaxel-treated patient cohortβ
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By examining the III-tubulin status in the initial prostatic biopsies of patients subsequently treated for CRPC disease with docetaxelβ
chemotherapy, we investigated the usefulness of III-tubulin expression as a potential predictive tumor biomarker for response toβ
docetaxel. Of the 37 cases, 17 were positive for III-tubulin (9 with moderate and 8 with strong staining) whereas 20 were negative.β
Representative examples of staining are shown in . In this cohort, III-tubulin expression was significantly correlated withFig. 4A and 4B β
a Gleason score >7 at diagnosis; 29.4  of III-tubulin-negative cancers were graded 8 or more as compared to 63.2  of % β % β
III-tubulin-positive cancers (p 0.043). PSA responses were observed in 52  of III-tubulin-negative patients compared with 35  of = % β % β
III-tubulin-positive patients (p 0.337). Patients with III-tubulin positive tumours experienced shorter time-to-progression. Median= β
time-to-progression was 4.7 months in III-tubulin-positive patients compared with 9.8 months in III-tubulin-negative patients (Breslowβ β
p 0.149; log-rank p 0.522). Overall, the median survival time for the entire cohort was 25.3 months (95  CI: 16.5 34.2) and the observed= = % –
cumulative probabilities at years 1, 2, and 3 were 79.5 , 57.8 , and 43.7 , respectively. Median OS was significantly shorter for patients% % %
with III-tubulin positive tumours than those with III-tubulin-negative hormone-na ve tumours (13.5 versus 41.6 months, p 0.019; β β ï = Fig.
). Finally, baseline PSA levels measured prior to the first cycle of chemotherapy in these patients were also significantly related to OS.4C 
Multivariate analysis taking III-tubulin expression, baseline PSA, age, and duration of androgen deprivation therapy into account showedβ
that III-tubulin expression (HR 2.93; p 0.037) and baseline PSA level (HR 4.09; p 0.012) were independent predictors of OS.β = =
DISCUSSION
In prostate cancer, clinical data and histoprognostic parameters, separated or integrated into nomograms still fail at the individual level
to accurately determine the risk of biochemical or clinical relapse after local treatment ( , ). At CRPC stage, docetaxel-based33 34 
chemotherapy has proven to have some effectiveness in terms of overall response rates and survival in CRPC patients ( , ). However,4 5 
any selection of patients likely to benefit most from this form of chemotherapy is difficult and is often based simply upon patient age or
the presence of co-morbidities in individuals.
Numerous preclinical studies have reported that the selective overexpression of III-tubulin constitutes an important mechanism forβ
resistance to tubulin-binding agents in various cancer cell lines ( , ). Several clinical studies have shown that high levels of 19 35 –38 β
III-tubulin expression in tumor cells are associated with low response rates and poorer survival in patients treated with taxane-based
chemotherapies ( , ). Our findings in prostate cancer were consistent with the previous studies and highlight that the expression13 –17 39 
of III-tubulin is associated with non organ-confined disease, metastatic lymph nodes and PSA failure. Thus, tumor cell III-tubulinβ β
expression might characterize a general subclass of PCa patients with aggressive behavior and poor prognosis. This could give reason to
consider adjuvant treatments for patients with III-tubulin positive tumors.β
Characteristics of our HNPC patient s cohort differed slightly from characteristics of patients who actually undergo a radical’
prostatectomy. The advent of PSA testing has lead to a considerable stage migration with an increase of low-risk prostate cancers. In our
HNPC cohort study, we included patients who underwent radical prostatectomy since 1988. This constitutes a selection bias due a more
important proportion of high-risk prostate cancer before the PSA era. These discrepancies may limit the study of III-tubulin expression asβ
the number of high-risk prostate cancers decreases over time. However, we showed that the prognostic impact of III-tubulin remainedβ
significant in organ-confined PCa and therefore, we posit that the III-tubulin is of additional value to well-established histoprognosticβ
parameters even in the assessment of presumed low-risk PCa.
We also observed here that the III-tubulin expression in AI PCa cell lines was increased in response to acute or chronic exposure toβ
docetaxel. In line with our findings, Ranganathan et al. previously showed an increase in III-tubulin expression in response to paclitaxelβ
treatment of DU145 cells ( ). The exact mechanism by which increased expression of III-tubulin mediates drug resistance remains open19 β
to debate. In some instances, we found that alterations of III-tubulin expression were associated with changes in cell morphology and/orβ
cell proliferation rate. Thus, there is reason to believe that these events might be key determinants of drug resistance. Additionally,
evidence is accumulating that microtubules containing III-tubulin exhibit an aberrant dynamicity. These microtubules are less stable thanβ
microtubules composed of other -tubulin isotypes ( , , , ) Since the primary effect of taxane is to bind microtubules therebyβ 9 10 40 41 
enhancing the microtubule polymerization and decreasing microtubule dynamicity, it has been suggested that III-tubulin-containingβ
microtubules are more prone to overcome the suppressive effects of taxanes on microtubule dynamics. Although it should be noted that all
the above studies ( , , ) have focused on the assembly of purified microtubules in cell free systems and therefore remain12 13 43 
controversial given contradictory reports obtained in intact cells, and hence more biologically relevant, that III-tubulin did notβ
intrinsically affect microtubule dynamic, at least in some instances ( , ). Interestingly, in these last studies, the effects of paclitaxel on38 42 
microtubule dynamics were altered, suggesting a role for III-tubulin in drug-microtubule interactions. Consistent with this, Mozetti et al.β
have reported that III-tubulin overexpression was the prominent mechanism of paclitaxel resistance in ovarian cancer patients, asβ
compared with other mechanisms of drug resistance such as overexpression of MDR-1 and point mutations in tubulin at the binding site of
paclitaxel ( ). Although many studies have focused on paclitaxel, such characteristics might also be pertinent for docetaxel. Interestingly,43 
recent reports further showed that III-tubulin confers resistance to microtubule-destabilizing agents such as vinorelbine in breast cancerβ
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cells ( ). In the setting of non-small cell lung cancer, III-tubulin was shown to impact significantly on the response to both tubulin44 β
targeting-agents and DNA-damaging agents ( ). The investigators proposed that III-tubulin may serve as a survival factor to rescue45 β
tumor cells from death signals triggered by chemotherapeutic agents. Therefore, it is conceivable that elevated expression of III-tubulinβ
can exert similar effects in other malignancies, including prostate cancer, and future work should explore this question.
Another interesting open question regarding antimicrotubule drug resistance associated with changes in III-tubulin expression inβ
cancer cells is: what is the contribution of other isotypes in response to taxane-based regimens? Ranganathan et al. have previously noted
that class IVb -tubulin was increased collaterally in III-tubulin-transfected DU145 cells in response to paclitaxel treatment ( ). In aβ β 20 
separate study, wherein paclitaxel-resistant DU145 variants were selected after chronic exposure to the drug, examination of the -tubulinβ
isotype composition revealed increased expression of III-tubulin but no changes were observed for IVb -tubulin. Instead, some increaseβ β
in IVa -tubulin expression was noted ( ). Although this previous work in DU145 has suggested that III-tubulin expression isβ 19 β
upregulated in response to paclitaxel treatment, our survey using docetaxel treatment of two androgen-independent AR-positive PCa cells,
22Rv1 and LNCaP-AI provides additional evidence that this situation might be relevant in clinical settings. These studies further indicate
that expression of the class II tubulin can be altered in PCa cells and highlight a potential role for this isotype in the emergence ofβ
docetaxel resistance. The ectopic overexpression or silencing of III-tubulin resulted in a seeming specific up- or downregulation of the β β
II-tubulin expression, respectively. Surprisingly, under these conditions, we failed to find any significant changes in the expression of other
-tubulin isotypes. These instances strengthened the role of III-tubulin in contributing to chemosensitvity and illustrate the importance ofβ β
monitoring the -tubulin isotype profile to confirm the contribution of the target isotype in drug response studies. Although previous workβ
has suggested that manipulation of II- and IVb-tubulin expression did not cause changes in paclitaxel sensitivity of CHO and lungβ β
cancer cells ( , ), these cell lines differ from prostate cancer cells, and future work is warranted in order to determine the full46 47 
functional implications of each -tubulin isotype in the emergence of drug-resistance in prostate cancer cells.β
Our findings in experimental prostate cancer cell lines were consistent with our clinical observations that III-tubulin expression inβ
prostate tumors correlated significantly with outcomes of docetaxel chemotherapy for CRPC patients. Patients expressing III-tubulin atβ
diagnosis had reduced survival. Thus it is tempting to speculate that the assessment of III-tubulin expression could determine whichβ
CRPC patients might benefit from taxane-based chemotherapy. Studies exploring potential molecular markers in response to
chemotherapy are currently limited by the difficulty in obtaining tissues from patients with CRPC. Many changes occurred during the
evolution to CRPC, and cancer tissue at diagnosis does not always reflect accurately the cancer tissue in its more advanced stage. In fact,
obtaining tumor tissue at CRPC stage, or before and during therapy, though rarely feasible in clinical practice, would certainly be the best
way to investigate the impact of biomarker on response to therapy. Nevertheless, by examining III-tubulin expression in the tumors ofβ
HNPC patients, which are easily accessible to tumor sampling, it seems possible to evaluate their response to docetaxel-based therapy once
the disease has progressed to CRPC. If these findings are confirmed, the use of novel tubulin-targeted agents, such as epothilones, could be
useful for III-tubulin-positive PCa patients ( , , ). This might also offer the opportunity for therapeutic intervention by an anti-β 11 48 49 β
III-tubulin treatment in such patients.
Collectively, our results suggest that the functional and clinical biomarker aspects of III-tubulin expression are linked. Consistentβ
with our previous findings and other studies reporting an increase in the III-tubulin isotype as a result of anti-microtubule drug treatmentsβ
( , , ), it seems likely that adjuvant treatments other than the current taxane-based chemotherapy regimen may be required for this19 20 50 
group of patients. More importantly, our results now support the idea that III-tubulin expression may be linked to multiple forms of PCa;β
progression to recurrence in HNPC patients, progression to CRPC in hormone-treated patients and, finally, progression to docetaxel
resistance in docetaxel-treated CRPC patients. In the area of cancer treatment, clinicians have to deal with two limitations: the difficulty to
predict accurately the relapse after local treatment; and the ability to anticipate ineffective adjuvant or systemic therapy. To date, in
prostate cancer, new molecular markers are needed to better define the subset of patients who are most likely to benefit from an adjuvant
strategy after radical treatment, and from chemotherapy at CRPC stage. Our findings were consistent with the role of III-tubulinβ
expression as prognostic marker of biochemical recurrence at HNPC stage. Assessment of the III-tubulin expression in cancer tissueβ
therefore could be useful to identify and monitor prostate cancer at high risk for recurrence after radical prostatectomy. If longer follow-up
and rates of specific mortality confirm these results, the III-tubulin expression might be interesting for predicting recurrence rates and forβ
proposing adjuvant therapy.
Functional overexpression or knockdown of III-tubulin modulates the prostate cancer cell lines sensitivity to docetaxel. The tissue β β
III-tubulin expression status also has predictive value in terms of OS in patients receiving docetaxel-based chemotherapy for
hormone-independent disease. These findings underline the importance of III-tubulin expression, which could be used in addition toβ
clinicopathologic characteristics to select patients for docetaxel-based chemotherapy. Prospective studies incorporating III-tubulinβ
immunohistochemistry are warranted to determine the clinical relevance of routine use of this assay.
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Figure 1
Prognostic value of III-tubulin expression in predicting the biochemical recurrence after radical prostatectomy in HNPC prostate cancerβ
patients
. Representative staining for III-tubulin in HNPC TMAs: absence of staining (A), moderate staining (B), strong staining (C).A, B, C β
Photomicrographs are taken at x20 objective magnification (A C) and x10 objective magnification; insets (A C). Scale Bar, 100 m. – – μ D. 
Recurrence-free survival (RFS) curves stratified by the expression of III-tubulin (negativity versus positivity of immunostaining, log-rankβ
test; p 0.002). HNPC: hormone naive prostate cancer; TMA: tissue micro-array.=
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Figure 2
Links between III-tubulin expression and the acquisition of docetaxel resistance in androgen-sensitive and androgen-insensitive prostateβ
cancer cells
. Time course expression of III-tubulin, total -tubulin and -tubulin isotypes in LNCaP-AI cells cultivated at 3 nmol/L docetaxel. .A β β β B 
Increased protein expression was confirmed by Western blotting: untreated 22Rv1 compared with 22Rv1 cultivated in the presence of 15
nmol/L docetaxel. Differential expression of III-tubulin between control vector-transfected cells and III-tubulin transfected clones wasC. β β
assessed by immunoblotting. A significant increase in levels of III-tubulin protein was observed in the III-tubulin transfected LNCaP cells (β β
III-tubulin clone 1 and III-tubulin clone 7) compared with the control vector-transfected LNCaP cells. Dose response curve assessing theβ β D. 
effect of III-tubulin overexpression in LNCaP cells. Cell viability assays showed that III-tubulin transfected LNCaP cells (clone 1 and 7)β β
were significantly more resistant to docetaxel treatment than control vector-transfected LNCaP cells. Points, mean; bars, SEM.
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Figure 3
Functional overexpression and knockdown of III-tubulin modulates the androgen-independent prostate cancer cells sensitivity to docetaxelβ
Differential levels of III-tubulin protein between control vector-transfected and III-tubulin transfected (clone 5 and 7) DU145 cells:A. β β
Western blot analysis showed that. The III-tubulin clone 5 expressed a similar level of III-tubulin compared with control vector-transfectedβ β
cells, whereas the III-tubulin clone 7 showed a higher level of III-tubulin expression. β β Dose response curve assessing the effect of B. β
III-tubulin overexpression in androgen-independent DU145 cells. Cell viability assays showed that clone 7 was significantly more resistant to
docetaxel treatment relative to III-tubulin clone 5 and control vector-transfected DU 145 cells. Points, mean; bars, SEM. NT: non targeting. β
Western blot confirmation of III-tubulin knockdown in 22Rv1 cells after siRNA transfection. The III-tubulin protein level was decreasedC. β β
72 hours after transfection and lasted at least 6 days after a single transfection. Dose response curve assessing the effect of III-tubulinD. β
silencing in androgen-independent 22Rv1 cells. Cell viability assays showed that III-tubulin siRNA-transfected 22Rv1 cells wereβ
significantly more sensitive to docetaxel treatment relative to non targeting siRNA-transfected and non-transfected 22Rv1 cells. Points, mean;
bars, SEM.
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Figure 4
Predictive value of III-tubulin expression for response to docetaxel in castration-resistant prostate cancer patientsβ
Representative staining for III-tubulin in prostate biopsy cores: absence of staining (A), staining positivity (B). Photomicrographs areA, B. β
taken at x20 objective magnification (A B), insets x5 objective magnification (AC). Scale Bar, 100 m. – μ Overall survival inC. 
docetaxel-treated patients: stratification by III-tubulin expression in prostatic tissue (negativity versus positivity of immunostaining, log-rankβ
test; p 0.019): expression of III-tubulin in prostate cancer tissue is significantly predictive for poorer survival in docetaxel-treated patients.= β
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Table 1
Patient s cohort characteristics of the HNPC cohort.’
Age, years :
Mean 64.5
Median 65.0
Range 47.1 75.0–
PSA, ng/ml:
Mean 14.2
Median 9.4
Range 1.4 113.0–
Prostate weight, gr:
Mean 55.6
Median 50.0
Range 10.0 210.0–
Clinical stage, No ( ):%
T1 175 (67.8)
T2 or more 83 (32.2)
Gleason score, No ( ):%
≤6 123 (47.7)
7 73 (28.3)
≥8 62 (24.0)
pT stage, No ( ):%
pT2 150 (58.1)
pT3 86 (33.4)
pT4 22 (8.5)
Extraprostatic extension, No ( ):% 96 (37.2)
Positive margins, No ( ):% 56 (21.7)
Seminal vesicle invasion, No ( ):% 56 (21.7)
Positive lymph nodes, No ( ):% 23 (8.9)
Duration of follow-up, months:
Mean 61.5
Median 48.3
Range 0.6 170.7–
Recurrence, No ( ):% 62 (24.0)
Clinico-pathological characteristics of patients with clinically hormone na ve prostate cancer (n 258).ï =
HNPC: hormone naive prostate cancer.
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Table 2
Association between III-tubulin expression and clinico-pathologic parameters.β
Patients with no TUBB3 expression n 215= Patients with TUBB3 expression n 43= Univariate analysis
p OR 95 CI[ % ]
Age, No ( ):%
<65 years 105 (48.8) 19 (44.2) 0.577
>65 years 110 (51.2) 24 (55.8)
Age, years (mean) 64.6 63.8 0.399
Clinical stage, No ( ):%
T1 151 (70.2) 25 (58.2) 0.068
T2 or more 64 (29.8) 18 (41.9)
PSA, No ( ):%
<10 ng/ml 119 (55.3) 19 (44.2) 0.180
>10 ng/ml 96 (44.7) 24 (55.8)
PSA, ng/ml (mean) 13.1 19.5 0.066
Gleason score, No ( ):%
≤7 172 (80.0) 24 (55.8) 0.001 3.17 1.59 6.30[ – ]
≥8 43 (20.0) 19 (44.2)
Primary Gleason grade 4 or 5, No ( ):% 72 (33.5) 23 (53.5) 0.013 2.28 1.18 4.43[ – ]
Prostate weight, No ( ):%
<50 gr 88 (40.9) 22 (51.2) 0.264
>50 gr 127 (59.1) 21 (48.9)
Prostate weight, gr (mean) 55.9 54.2 0.724
pT stage, No ( ):%
pT2 131 (60.9) 19 (44.2) 0.042 1.97 1.02 3.82[ – ]
pT3-4 84 (39.1) 24 (55.8)
Extracapsular extension, No ( ):% 74 (34.4) 22 (51.2) 0.028 2.10 1.08 4.09[ – ]
Positive surgical margins, No ( ):% 43 (20.0) 13 (30.2) 0.116
Seminal vesicle invasion, No ( ):% 42 (19.5) 14 (32.6) 0.059
Positive lymph nodes, No ( ):% 15 (7.0) 8 (18.6) 0.034 3.05 1.20 7.73[ – ]
Recurrence, No ( ):% 46 (21.4) 16 (37.2) 0.029 2.15 1.07 4.33[ – ]
Duration of follow-up, months (mean) 62.1 58.4 0.603
Clinical data, pathologic features, PSA failure: correlations with III-tubulin expression in HNPC samples (univariate analysis). HNPC: hormone naive prostate cancer; PSA: prostate specific antigen.β
